Medicaid Rebates To Increase $3.95bn With Revision For Line Extensions
Executive Summary
CMS issues interim final rule to ensure there’s ‘no confusion’ that line extensions are now subject to higher Medicaid rebate requirements.
You may also be interested in...
What Is A ‘Line Extension’? Medicaid Tries Again With Sweeping Definition
In the latest reminder of how badly industry lost the argument over the value of incremental improvements in formulations, US is proposing enhanced Medicaid rebates on virtually all new formulations of existing brands.
Abuse-Deterrent Exemption From Medicaid Rebates Hinges On FDA Standards
Opioid formulations with abuse-deterrent properties will be exempt from Medicaid price-inflation rebates if they meet FDA standards, Centers for Medicare and Medicaid Services says in guidance to manufacturers.
Medicaid Add-On Rebates For Line Extensions Remain A Judgment Call
Manufacturers must continue to use their discretion on which line extensions should be subject to inflation-based Medicaid rebates in lieu of guidance from CMS in its recent AMP final rule.